LANCET HAEMATOLOGY, cilt.6, sa.2, 2019 (SCI-Expanded)
Background Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases.